Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma

Jonathon B. Cohen, Madhusmita Behera, Carrie A Thompson, Christopher R. Flowers

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Up to 50% of patients with Hodgkin lymphoma and diffuse large B-cell lymphoma will relapse, requiring additional therapy. Although surveillance imaging is commonly performed in clinical practice, its ability to identify asymptomatic relapses and improve survival for patients is not well defined. We evaluated the surveillance imaging role in relapse detection and reviewed its impact on survival for relapsed patients, and found that current imaging approaches do not detect most relapses prior to clinical signs and symptoms or improve survival.

Original languageEnglish (US)
Pages (from-to)561-564
Number of pages4
JournalBlood
Volume129
Issue number5
DOIs
StatePublished - Feb 2 2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Hodgkin Disease
Cells
Imaging techniques
Recurrence
Survival
Signs and Symptoms
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. / Cohen, Jonathon B.; Behera, Madhusmita; Thompson, Carrie A; Flowers, Christopher R.

In: Blood, Vol. 129, No. 5, 02.02.2017, p. 561-564.

Research output: Contribution to journalArticle

Cohen, Jonathon B. ; Behera, Madhusmita ; Thompson, Carrie A ; Flowers, Christopher R. / Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. In: Blood. 2017 ; Vol. 129, No. 5. pp. 561-564.
@article{06aaf2f96b4e4b60a5ab1c4fe50b2902,
title = "Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma",
abstract = "Up to 50{\%} of patients with Hodgkin lymphoma and diffuse large B-cell lymphoma will relapse, requiring additional therapy. Although surveillance imaging is commonly performed in clinical practice, its ability to identify asymptomatic relapses and improve survival for patients is not well defined. We evaluated the surveillance imaging role in relapse detection and reviewed its impact on survival for relapsed patients, and found that current imaging approaches do not detect most relapses prior to clinical signs and symptoms or improve survival.",
author = "Cohen, {Jonathon B.} and Madhusmita Behera and Thompson, {Carrie A} and Flowers, {Christopher R.}",
year = "2017",
month = "2",
day = "2",
doi = "10.1182/blood-2016-08-685073",
language = "English (US)",
volume = "129",
pages = "561--564",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma

AU - Cohen, Jonathon B.

AU - Behera, Madhusmita

AU - Thompson, Carrie A

AU - Flowers, Christopher R.

PY - 2017/2/2

Y1 - 2017/2/2

N2 - Up to 50% of patients with Hodgkin lymphoma and diffuse large B-cell lymphoma will relapse, requiring additional therapy. Although surveillance imaging is commonly performed in clinical practice, its ability to identify asymptomatic relapses and improve survival for patients is not well defined. We evaluated the surveillance imaging role in relapse detection and reviewed its impact on survival for relapsed patients, and found that current imaging approaches do not detect most relapses prior to clinical signs and symptoms or improve survival.

AB - Up to 50% of patients with Hodgkin lymphoma and diffuse large B-cell lymphoma will relapse, requiring additional therapy. Although surveillance imaging is commonly performed in clinical practice, its ability to identify asymptomatic relapses and improve survival for patients is not well defined. We evaluated the surveillance imaging role in relapse detection and reviewed its impact on survival for relapsed patients, and found that current imaging approaches do not detect most relapses prior to clinical signs and symptoms or improve survival.

UR - http://www.scopus.com/inward/record.url?scp=85014805879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014805879&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-08-685073

DO - 10.1182/blood-2016-08-685073

M3 - Article

C2 - 27956385

AN - SCOPUS:85014805879

VL - 129

SP - 561

EP - 564

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -